stockrowAlkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
- Revenue
- +21.8%
- EPS
- −80.6%
- Free cash flow
- +6.78%
Quarter to September 2026, against a year earlier
Follow ALKS
Alert me
Alkermes plc (ALKS) Shares outstanding
Alkermes plc's shares outstanding at the end of fiscal 2025 was $168.7M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $176.4M. Over the past ten years it has ranged from $149.2M (fiscal 2015) to $169.7M (fiscal 2023); the current reading is higher than 82% of that period. Alkermes plc ranks 19th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $168.7M | (0.27%) |
| FY2024 | $169.2M | (0.31%) |
| FY2023 | $169.7M | 3.66% |
| FY2022 | $163.7M | (0.61%) |
| FY2021 | $164.8M | 3.75% |
| FY2020 | $158.8M | 1.12% |
| FY2019 | $157.1M | 1.25% |
| FY2018 | $155.1M | 1.11% |
| FY2017 | $153.4M | 1.27% |
| FY2016 | $151.5M | 1.53% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $176.4M | 1.67% |
| Jun 2026 | $173.5M | 4.38% |
| Mar 2026 | $166.2M | (1.51%) |
| Dec 2025 | $168.7M | 0.14% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RDY Dr. Reddy's Laboratories Ltd compare | $833.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $335.7M |
| HIMS Hims & Hers Health, Inc. compare | $231.7M |
| ALKS Alkermes plc | $176.4M |
| SUPN Indivior Pharmaceuticals Inc. compare | $122.0M |
| LQDA Liquidia Corporation compare | $101.4M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $84.9M |
| LNTH Lantheus Holdings, Inc. compare | $68.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ALKS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement